Scinai Immunotherapeutics Ltd ADR (NASDAQ: SCNI)’s stock price has decreased by -8.84% compared to its previous closing price of $2.49. However, the company has seen a -9.92% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-12 that CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM, June 12, 2025 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman’s participation in the BIO International Convention 2025 (June 16–19, Boston).
Is It Worth Investing in Scinai Immunotherapeutics Ltd ADR (NASDAQ: SCNI) Right Now?
Scinai Immunotherapeutics Ltd ADR (NASDAQ: SCNI) has a price-to-earnings ratio of 0.39x that is above its average ratio. Additionally, the 36-month beta value for SCNI is 1.86. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SCNI is 0.83M and currently, short sellers hold a 4.97% ratio of that float. The average trading volume of SCNI on July 03, 2025 was 374.58K shares.
SCNI’s Market Performance
SCNI’s stock has seen a -9.92% decrease for the week, with a -9.20% drop in the past month and a -19.22% fall in the past quarter. The volatility ratio for the week is 14.35%, and the volatility levels for the past 30 days are at 16.84% for Scinai Immunotherapeutics Ltd ADR The simple moving average for the last 20 days is -5.71% for SCNI stock, with a simple moving average of -27.92% for the last 200 days.
SCNI Trading at -11.69% from the 50-Day Moving Average
After a stumble in the market that brought SCNI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.55% of loss for the given period.
Stock Fundamentals for SCNI
Current profitability levels for the company are sitting at:
- -1.56 for the present operating margin
- -0.47 for the gross margin
The net margin for Scinai Immunotherapeutics Ltd ADR stands at 3.51. The total capital return value is set at -0.18. Equity return is now at value 138.38, with 24.20 for asset returns.
Based on Scinai Immunotherapeutics Ltd ADR (SCNI), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -5.28. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -0.87.
Currently, EBITDA for the company is 7.87 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 1.72. The receivables turnover for the company is 10.34for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.32.
Conclusion
In conclusion, Scinai Immunotherapeutics Ltd ADR (SCNI) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
